N/A
N=40
Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy
Cow's Milk Allergy
Bottom Line
View on ClinicalTrials.gov: NCT02414243 ↗Enrolled (actual)
40
Serious AEs
2.6%
Results posted
Jan 2020
Primary outcome: Primary: Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula — 0; 0; 0; 30 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- New Amino Acid formula (Other); Commercially available Amino Acid Formula (Other)
- Age
- Pediatric
- Sex
- All
- Sponsor
- Laboratorios Ordesa
- Primary completion
- Dec 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula |
0; 0; 0; 30; 30; 30 | — |
| SECONDARY Cow's Milk Allergy Related Symptoms |
1.37; 0.79 | — |
Summary
This is a prospective, controlled, multi-country study to verifying the hypoallergenicity of the new amino acid-based formula in infants and children aged< 12 years with documented cow's milk protein allergy (CMPA).
Eligibility Criteria
Inclusion Criteria
- Children with documented cow's milk allergy, confirmed by one of the following criteria, within six months prior to study start (visit 2):
- Positive double-blind, placebo-controlled oral food challenge (DBPCFC) with cow's milk OR
- Positive open or single-blind oral food challenge with cow's milk carried out under the supervision of a specialist in children with clear immediate reactions and a positive test for specific IgE (in serum [sIgE>0,35 KUI/L] or skin prick test [SPT ≥ 3 mm]) OR
- Reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and detectable serum milk-specific IgE or positive skin prick test
- Aged ≤12 years of age at screening.
- Expected consumption of a minimum of 250ml of study formula per day during the open challenge.
- Written informed consent from one or both parents (depending on the local legislation) or legal representative.
Exclusion Criteria
- Children who receive breastfeeding at study enrolment.
- Had any chronic medical diseases, chromosomal or major congenital anomalies, or major gastrointestinal disease/abnormalities (other the CMPA); had immunodeficiency; antihistamine [excluding eye drops] use in 7 days prior to a food challenge or oral steroid use within 14 days prior to enrolment; unstable asthma; severe uncontrolled eczema;
- Severe anaphylactic reaction [required ≥ 2 doses of epinephrine] to milk or breast milk within the past 2 years;
- Existing illness that could interfere with formula acceptance or identification of allergic reactions.
- Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.
- Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.
Data sourced from ClinicalTrials.gov (NCT02414243). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.